Matches in SemOpenAlex for { <https://semopenalex.org/work/W2945124725> ?p ?o ?g. }
Showing items 1 to 41 of
41
with 100 items per page.
- W2945124725 abstract "Platelet survival time (SURV) has correlated with a history of thromboembolism (TE) in patients with rheumatic heart disease (RHD). A controlled trial of sulfinpyrazone (SFP) in RHD is in progress and 138 patients have been entered. SURV (51Chromium labelling) was shortened (2.3 ± 0.08 days; AVE t 1/2 ± SEM; normal 3.7 ± 0.04 days) in 40 of 41 (98%) with a history of TE and in 76 of 97 (78%) (2.9 ± 0.07 days; P<0.001) of those without a history of TE. One hundred sixteen with shortened SURV have been randomized to SFP or placebo and 67 have either completed four years (N=37), undergone mitral valve replacement (N=18) (ave 19 months; range 6-32 months), had definite TE (N=8) (average 14 months; range 8-23 months) or died (N=4) (average 15 months; range 5-22 months). Definite TE (prolonged neurologic deficit) occurred in one on SFP and in seven on placebo (all with shortened SURV) (X2 = 4.31; NS). SFP increased SURV (2.4 ± 0.12 to 2.7 ± 0.13 days; N=23; P<0.001) and 12 (52%) had an increase in SURV of >0.02 days. The patient on SFP with new TE had no change in SURV (2.3 to 2.3 days). Placebo did not alter SURV (2.4 ± 0.15 to 2.5 ± 0.08 days; N=26; NS) and two (8%) had an alteration of SURV by > 0.02 days. SURV was not altered in patients with normal SURV (3.7 ± 0.08 to 3.6 ± 0.08 days; N=12; NS) and no patient with normal SURV has had shortened SURV on subsequent yearly measurement. Patients with normal SURV were not randomized. Results suggest that SURV is shortened in patients with RHD who have had or will have TE, that SFP increases SURV and may prevent TE in these patients." @default.
- W2945124725 created "2019-05-29" @default.
- W2945124725 creator A5041531882 @default.
- W2945124725 creator A5079830544 @default.
- W2945124725 creator A5085044256 @default.
- W2945124725 date "1977-01-01" @default.
- W2945124725 modified "2023-09-27" @default.
- W2945124725 title "Controlled Trial of Sulfinpyrazone in Rheumatic Heart Disease. Preliminary Results" @default.
- W2945124725 doi "https://doi.org/10.1055/s-0039-1680602" @default.
- W2945124725 hasPublicationYear "1977" @default.
- W2945124725 type Work @default.
- W2945124725 sameAs 2945124725 @default.
- W2945124725 citedByCount "0" @default.
- W2945124725 crossrefType "proceedings-article" @default.
- W2945124725 hasAuthorship W2945124725A5041531882 @default.
- W2945124725 hasAuthorship W2945124725A5079830544 @default.
- W2945124725 hasAuthorship W2945124725A5085044256 @default.
- W2945124725 hasBestOaLocation W29451247251 @default.
- W2945124725 hasConcept C126322002 @default.
- W2945124725 hasConcept C164705383 @default.
- W2945124725 hasConcept C177713679 @default.
- W2945124725 hasConcept C2777628954 @default.
- W2945124725 hasConcept C2777738910 @default.
- W2945124725 hasConcept C2780074459 @default.
- W2945124725 hasConcept C71924100 @default.
- W2945124725 hasConceptScore W2945124725C126322002 @default.
- W2945124725 hasConceptScore W2945124725C164705383 @default.
- W2945124725 hasConceptScore W2945124725C177713679 @default.
- W2945124725 hasConceptScore W2945124725C2777628954 @default.
- W2945124725 hasConceptScore W2945124725C2777738910 @default.
- W2945124725 hasConceptScore W2945124725C2780074459 @default.
- W2945124725 hasConceptScore W2945124725C71924100 @default.
- W2945124725 hasLocation W29451247251 @default.
- W2945124725 hasOpenAccess W2945124725 @default.
- W2945124725 hasPrimaryLocation W29451247251 @default.
- W2945124725 hasRelatedWork W2038358121 @default.
- W2945124725 hasRelatedWork W2408493669 @default.
- W2945124725 isParatext "false" @default.
- W2945124725 isRetracted "false" @default.
- W2945124725 magId "2945124725" @default.
- W2945124725 workType "article" @default.